TECH · XBRL financial data

BIO-TECHNE financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (TECH's year ends in late June)

In millions of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Revenue	—	—	—	year only	289	297	316	317*	287	296	311	321*
Revenue from contracts with customers	277	273	303	306*	289	297	316	317*	287	296	311	321*
Cost of goods and services sold	92	96	99	103*	106	103	102	118*	98	105	103	110*
Gross profit	185	177	205	203*	183	194	215	199*	188	191	208	211*
Selling, general and administrative	105	116	112	134*	119	121	151	197*	116	114	109	113*
Total operating expenses	129	139	138	158*	143	146	176	223*	140	137	133	137*
Operating income (loss)	56	38	67	46*	40	47	39	(24)*	48	54	75	74*
Interest expense	5	4	4	3*	2	2	2	2*	3	2	2	2*
Other income (expense)	—	—	—	year only	—	—	—	year only	—	—	—	year only
Income tax expense (benefit)	(1)	6	12	1*	7	8	16	(5)*	10	13	20	16*
Net income (loss)	51	27	49	41*	34	35	23	(18)*	38	38	51	—
Earnings per share, basic USD per share	0.32	0.17	0.31	0.26*	0.21	0.22	0.14	(0.11)*	0.25	0.24	0.33	—
Earnings per share, diluted USD per share	0.31	0.17	0.31	0.25*	0.21	0.22	0.14	(0.11)*	0.24	0.24	0.32	—
Weighted average shares, basic millions of shares	158	158	157	158*	159	158	157	156*	155	156	156	156*
Weighted average shares, diluted millions of shares	162	160	160	161*	161	161	159	158*	156	157	157	157*

Fiscal quarters (TECH's year ends in late June)

In millions of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Cash and cash equivalents	149	130	140	152	188	178	141	162	145	173	210	265
Short-term investments	—	6	5	1	—	0	0	—	—	—	—	—
Accounts receivable	205	207	228	241	224	218	237	207	184	185	215	217
Inventory	186	181	179	180	185	188	191	189	203	205	201	196
Total current assets	591	591	611	617	649	635	627	608	610	637	688	744
Property and equipment, net	232	234	244	251	254	250	252	246	240	234	233	232
Right-of-use asset	102	101	97	91	89	85	84	73	71	68	68	67
Goodwill	969	980	971	973	983	965	969	981	979	981	978	975
Total assets	2,755	2,731	2,721	2,704	2,736	2,670	2,644	2,558	2,526	2,523	2,551	2,587
Accounts payable	28	32	29	38	32	33	32	25	30	26	23	27
Accrued liabilities	16	17	18	25	21	28	24	26	19	20	18	20
Total current liabilities	128	135	150	159	142	161	169	176	145	140	153	164
Lease liability, non-current	97	96	93	88	85	82	79	84	81	77	76	74
Retained earnings	1,328	1,261	1,298	1,325	1,341	1,287	1,196	1,066	1,083	1,107	1,145	1,144
Total stockholders' equity	1,998	1,964	2,014	2,069	2,139	2,078	2,018	1,919	—	2,011	2,085	2,108
Total liabilities and equity	2,755	2,731	2,721	2,704	2,736	2,670	2,644	2,558	2,526	2,523	2,551	2,587
Common shares outstanding (cover page) millions of shares	158	157	158	159	159	158	157	156	156	156	157	157

Fiscal quarters (TECH's year ends in late June)

In millions of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Net income (loss)	51	27	49	41*	34	35	23	(18)*	38	38	51	—
Stock-based compensation	10	13*	8*	7*	10	15*	11*	5*	12	14*	10*	5*
Depreciation and amortization	29	28*	27*	28*	28	27*	28*	27*	24	25*	24*	24*
Net cash from operating activities	59	83*	81*	75*	64	84*	41*	98*	28	82*	87*	95*
Purchases of property and equipment	14	15*	16*	18*	9	7*	10*	5*	5	6*	9*	8*
Net cash from investing activities	(154)	(24)*	(16)*	(9)*	(22)	(5)*	(9)*	0*	1	(6)*	(6)*	(7)*
Share repurchases	—	—	0*	0*	—	—	100*	100*	0	0*	0*	42*
Dividends paid	13	13*	13*	13*	13	13*	13*	12*	12	12*	13*	12*
Net cash from financing activities	72	(81)*	(52)*	(60)*	(12)	(84)*	(68)*	(90)*	(44)	(49)*	(43)*	(33)*
Net change in cash	(32)	(19)*	10*	12*	36	(10)*	(37)*	22*	(17)	28*	37*	55*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
United Therapeutics	1,803	783	314*	42.9M	—	Q2 FY26 10-QJun 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.